AbbVie terminates TREM2 program and collaboration with Alector after Phase 2 miss

Alector, Inc.

INVOKE-2 Phase 2 trial of AL002 in early Alzheimer's disease did not meet primary endpoint (announced Nov 25, 2024).
AbbVie provided written termination notice on Jan 9, 2025 for TREM2 program and the overall collaboration agreement.
Termination effective 30 days from receipt of Jan 9 termination letter; no other programs remain in the partnership.
The TREM2 program was the only remaining program under the AbbVie Agreement, so termination ends the entire collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.